Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Corgenix Announces Initial Phase Completion of Clinical Trial of Rapid Test for Lassa Fever

Published: Tuesday, April 23, 2013
Last Updated: Tuesday, April 23, 2013
Bookmark and Share
First-to-market, point-of-care rapid diagnostic test based on recombinant antigen technology for the detection of Lassa viral hemorrhagic fever filed for CE Marking.

Corgenix Medical Corporation announced completion of a major phase of the collaborative effort to combat important viral diseases.

The multi-year study, conducted primarily at the Kenema Government Hospital in Kenema, Sierra Leone, is investigating the clinical utility of several diagnostic products developed by Corgenix and other members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University. In this major study, scientists are using Consortium-developed recombinant antigen-based tests to evaluate patients presenting with clinical symptoms of Lassa hemorrhagic fever. Lassa fever is a dangerous, often fatal disease common to much of West Africa and is considered to be a bioterror threat throughout the world.

“We are very pleased to successfully complete the initial clinical testing phase of our Lassa product development program,” said Douglass Simpson, Corgenix President and CEO. “The first product, a rapid 15-minute test that detects Lassa virus antigen in blood, demonstrated outstanding clinical performance in our studies. It showed its potential to dramatically change the way this disease is detected and treated, with healthcare workers now able to diagnose Lassa infections in the early acute stage, leading to earlier treatment and potentially saving many lives.”

Corgenix said that the first of the products used in the studies, the ReLASVTM Antigen Rapid Test, will be advanced into full commercialization this year. Corgenix has submitted the study results to secure CE Marking, a regulatory requirement in Europe and many other countries.

Lassa virus is a category-A select agent, requiring biosafety level 4 (BSL-4) laboratories. It poses a high individual risk of aerosol-transmitted laboratory infections that cause severe to fatal disease in humans for which vaccines or other treatments are not available. Lassa virus causes Lassa hemorrhagic fever characterized by bleeding and coagulation abnormalities, with mortality rates reported exceeding 25 percent, with children and pregnant women being the highest risk groups. This new rapid test serves the urgent need for screening of suspected Lassa fever cases in the early stages of infection when patients exhibit milder symptoms that can lead to misdiagnosis.

Robert Garry, Ph.D., Professor of Microbiology and Immunology at the Tulane University School of Medicine and Principal Investigator of the Consortium, added, “We have been very pleased with the results of our collaborative effort over the past years. The diagnostic products for Lassa have shown to be remarkably effective in clinical settings in Africa and will have a meaningful impact on the health care in that part of the world, and will also fill a critical gap in bioterrorism defense.”

The Consortium will continue its research activities in Sierra Leone, Nigeria and other West African countries, advancing other laboratory tests for Lassa and other tropical viral diseases. The research will also assess the potential impact these new generation diagnostic products have on significantly reducing mortality rates through earlier treatment.

The Consortium Lassa products have not yet been cleared for use in the United States by the U.S. Food and Drug Administration (FDA).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Corgenix Announces Partnership with Health Diagnostic Laboratory
Corgenix Medical Corporation has announced a strategic partnership with Health Diagnostic Laboratory, Inc. for the development of a clinical Laboratory Developed Test.
Thursday, October 31, 2013
Corgenix Announces Diagnostic Development Agreement with Lilly
Companies to focus on potential companion diagnostic opportunity.
Thursday, May 23, 2013
Corgenix Expands Contract Services Business Unit
New dedicated website launched — highlights contract service capabilities, companion diagnostics.
Friday, May 03, 2013
Corgenix Announces Collaboration with SpectraCell Laboratories
Corgenix' AspirinWorks® product will be added to SpectraCell’s advanced cardiovascular assessment services.
Monday, July 28, 2008
Scientific News
Microdroplet Reactors Mimic Living Systems
Researchers use microdroplets to study non-equilibrium reactions like those in living organisms.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!